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Abstract
The dexamethasone suppression test is a useful endocrinological test to diagnose Cushing’s syndrome.  However, its interpretation may
be influenced by many factors such as stress, alcohol, failure to ingest the dexamethasone, altered metabolism, drug interaction and
obesity. This report illustrates such an instance, whereby the result of the test was erratic due to the anti-tuberculous drug rifampicin.
Rifampicin has been found to profoundly attenuate the biological effects of dexamethasone, probably by enhancing its metabolism in the
liver. The exact mechanism of the drug interaction remains elusive, though induction of hepatic CYP3A4 enzyme complex is a possible
mechanism. In a patient treated with rifampicin, the results of dexamethasone suppression tests thus have no diagnostic value and can be
very misleading. (Pol J Endocrinol 2010; 61 (6): 706–709)
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Streszczenie
Test hamowania z deksametazonem przeprowadza się w celu diagnostyki zespołu Cushinga. Na jego wynik wpływa wiele czynników,
takich jak: stres, alkohol, upośledzenie wchłaniania i metabolizmu deksametazonu, interakcje międzylekowe  i otyłość. W pracy opisano
przypadek wpływu leku przeciwgruźliczego, ryfampicyny na wynik testu. Stwierdzono, że ryfampicyna w znacznym stopniu zmienia
biologiczny efekt działania deksametazonu, prawdopodobnie przez przyspieszenie jego metabolizmu w wątrobie. Dokładny mechanizm
interakcji pozostaje niewyjaśniony, choć prawdopodobna wydaje się indukcja wątrobowego kompleksu enzymu CYP3A4. Test hamowa-
nia deksametazonem przeprowadzony u pacjentów leczonych ryfampicyną nie posiada wartości dianostycznej, a jego wynik może być
mylący. (Endokrynol Pol 2010; 61 (6): 706–709)
Słowa kluczowe: test hamowania deksametazonem, ryfampicyna, zespół Cushinga, efekt biologiczny, interakcje międzylekowe
Introduction
Multiple drugs are often used in a single patient. Dur-
ing treatment, drug-drug interaction occurs when the
presence of one drug affects the pharmacodynamics and
pharmacokinetics of another drug through absorption,
metabolism or disposition and therefore affects the bio-
availability, efficacy and toxicity in the patient. We de-
scribe a patient with subtle signs of Cushing’s syndrome
who was also being treated for pulmonary tuberculo-
sis. In this report, we demonstrate an erratic dexam-
ethasone suppression test as a result of concurrent ad-
ministration of rifampicin that has been recognised to
be a liver enzyme inducer. The metabolism of dexam-
ethasone has been accelerated by rifampicin, thus pro-
ducing falsely abnormal results. Therefore, awareness
of this diagnostic pitfall is of paramount importance to
avoid unnecessary diagnostic tests and anxiety to the
patient.
Case report
A 30 year-old Indonesian man, who had been living in
Malaysia for the past two years, presented with dry
cough of three months’ duration associated with inter-
mittent haemoptysis. He had been having fever, night
sweats, appetite loss and profound weight loss. There
was no history of close contact with tuberculosis. He
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had an unremarkable medical and surgical history. He
was married with two children and indulged in no high
risk behaviour. He had no exposure to asbestos at work.
He was a heavy smoker but denied consuming alcohol.
He had been taking herbal medicine for his cough, but
had stopped three weeks prior to admission.
Clinically, he was cachexic with muscle wasting. He
was febrile, but his vital signs were normal. Respiratory
examination revealed signs of lung consolidation at
apical region bilaterally with multiple cervical lymphad-
enopathies. He was also noted to have subtle features
of Cushing’s syndrome. Although he did not look cush-
ingoid, there were prominent purple striae noted on
the abdominal wall, flank and thighs (Fig. 1). Multiple
acnes were also seen on the face and anterior chest wall
(Fig. 2). There was no proximal myopathy or thinning
of the skin. Other systemic examinations were normal.
The clinical diagnosis considered at the time of ad-
mission was pulmonary tuberculosis. Cushing’s syn-
drome was also suspected, despite only subtle clinical
signs.
Laboratory investigations revealed mild leucocyto-
sis with normal monocyte count. The renal and liver
functions were normal except for hypo-albuminaemia.
The erythrocyte sedimentation rate was 78 mm/hour.
The Mantoux test was strongly positive but the spu-
tum was negative for acid fast bacilli (AFB). The chest
radiograph showed reticulo-nodular opacities over both
lung fields, with evidence of bilateral apical pleural
thickening. These findings were consistent with second-
ary tuberculosis (Fig. 3).
He was started on anti-tuberculous drugs: isoniazid
300 mg daily, rifampicin 600mg daily, ethambuthol 1.2 g
daily, pyrazinamide 2 g daily and pyridoxine 10 mg
daily.
In view of the possible Cushing’s syndrome, he was
further investigated while his anti-TB treatment was
continued (Table I).
The 1 mg overnight dexamethasone test showed
failure of suppression with serum cortisol of 74nmol/L
(normal < 50 nmol/L). A further test with low dose DST
showed serum cortisol was suppressed. However, in
view of a detectable level of ACTH, ACTH-dependent
Cushing’s syndrome was entertained. We therefore
proceeded with high dose DST. The result however
Figure 1. The presence of abdominal purplish striae that prompted
the initial suspicion of Cushing’s syndrome in this patient with
pulmonary tuberculosis
Rycina 1. Purpurowe rozstępy na skórze brzucha i ud sugerujące
wstępne rozpoznanie zespołu Cuschinga u chorego z gruźlicą płuc
Figure 2. The multiple acnes on the anterior chest wall
Rycina 2. Liczne zmiany trądzikowe na przedniej ścianie klatki
piersiowej
Figure 3. The AP view chest radiograph of this patient  shows the
reticulo-nodular shadows of both lung apices which is consistent
with secondary pulmonary tuberculosis
Rycina 3. Na zdjęciu RTG klatki piersiowej w projekcji przednio-
-tylnej widoczne smużasto-guzkowe zacienienia w szczytach obu
płuc odpowiadające obrazowi wtórnej gruźlicy płuc
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failed to confirm our suspicion. The baseline serum cor-
tisol was also found to be low, which again made the
diagnosis unlikely. These tests were done on days 6,
11 and 17 respectively. In view of the conflicting results,
the basal and midnight serum cortisol were performed
and showed an intact diurnal variation of cortisol se-
cretion. An abdominal ultrasound examination exclud-
ed adrenal tumour. We could not explain the clinical
signs that mimicked Cushing’s syndrome, but given the
above result we concluded that he did not in fact have
Cushing’s syndrome. The results were erratic due to
concurrent treatment with rifampicin which is a liver
enzyme inducer. This mechanism might have caused
attenuation of the dexamethasone metabolism, causing
a falsely high serum cortisol level in the overnight dex-
amethasone suppression test. We planned to repeat the
test after the anti-tuberculous treatment, but the patient
was defaulted from our follow-up.
Discussion
This patient was admitted with a diagnosis of pulmo-
nary tuberculosis and was found to have subtle clinical
signs of Cushing’s syndrome — acnes and purplish ab-
dominal and thigh striae. A suspicion of Cushing’s syn-
drome was made and subsequently he was subjected
to a series of endocrinological tests using dexametha-
sone suppression test while he was treated with anti-
tuberculous drugs including rifampicin, not realising
that it could profoundly affect the interpretation of test
results.
Rifampicin is a widely used drug for the treatment
of pulmonary tuberculosis. It is known that rifampicin
is a potent inducer of the hepatic oxygenase enzymes
involved in many drug metabolisms. Patients receiv-
Table I. Dexamethasone suppression test (DST) and ACTH
level.
Tabela I. Test hamowania deksametazonem (DST) i stężenia
ACTH
Test Baseline Post test Baseline
serum  serum  ACTH
Cortisol Cortisol [pg/mL]
[nmol/L] [nmol/L]
Overnight 1 mg DST 281 74
48 hours low doese DST 206 102 11.1
48 hours high dose DST 83 31 < 10.0
6 am 191
1200 am 55
ing rifampicin for the treatment of tuberculosis have
increased liver cytochrome P450 activity and intense pro-
liferation of the smooth endoplasmic reticulum [1, 2].
Many reports have found that rifampicin induces
profound alterations in cortisol metabolism when ad-
ministered to patients with primary adrenal failure re-
ceiving adequate corticosteroids replacement therapy
[3]. The half life and the systemic clearance of hydro-
cortisol was decreased and increased by about 35% re-
spectively. A study to evaluate the reliability of a stan-
dard overnight dexamethasone suppression test on
patients taking rifampicin concluded that the dexam-
ethasone test in such patients may mislead physicians
into diagnosing non-existent Cushing’s syndrome [4].
To the best of our knowledge, there has been no
complete report on the bioavailability of dexamethasone
in subjects treated with rifampicin. However, a Japa-
nese report found that in patients receiving rifampicin
therapy for tuberculosis, the half-life of dexamethasone
was decreased three fold and the clearance rate was
increased five fold [5]. It appears, therefore, that the
removal of dexamethasone by the liver was greatly ac-
celerated compared to that of cortisol and prednisolo-
ne, probably by several orders of magnitude, and was
the main reason for the failure to suppress serum corti-
sol, even when an adequate amount of dexamethasone
was administered. This suggests that the serum con-
centration, and presumably the quantity of dexametha-
sone reaching the pituitary or hypothalamus, in patients
receiving rifampicin were not sufficient to inhibit ACTH
or CRH secretion. Whatever the mechanism of interac-
tion in patients treated with rifampicin, the dexametha-
sone suppression test is rendered highly abnormal and
if applied in this patient could mislead the physician
into diagnosing non-existent Cushing’s syndrome. Al-
though no study has had the time required to restore
pituitary ACTH suppressibility to normal after discon-
tinuing rifampicin therapy, it would be prudent to stop
rifampicin therapy for 15 days before performing a dex-
amethasone suppression test. This judgment is based
on a report on the effect of rifampicin on the metoprolol
metabolism [6].
Applying this to our patient, he was treated with
rifampicin for pulmonary tuberculosis and subsequently
underwent various dexamethasone suppression tests
to diagnose Cushing’s syndrome. Although the results
from overnight DST were consistent with a diagnosis
of Cushing’s syndrome, he lacked the typical clinical
features of Cushing’s syndrome. We therefore conclud-
ed that these results were misled by the simultaneous
administration of rifampicin during the test. Following
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that, we decided to review him in six months’ time af-
ter he had completed his anti-tuberculous treatment,
when we planned to repeat the test. However, this pa-
tient was lost to our follow-up and we were not able to
repeat the test to confirm our suspicion.
Therefore, in screening patients for Cushing’s syn-
drome, it is important to be aware of potential drug-
drug interaction with dexamethasone, which may lead
to falsely positive and erratic results. Appropriate use
of investigations and interpretation of results is of par-
amount importance to avoid a false diagnosis that will
create anxiety in the patient.
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